NCT05563480 - TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

May 31, 2024

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection

TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

DRUG

Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection

Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

DRUG

TQB2618 injection; Penpulimab injection

TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

Trial Locations (4)

RECRUITING

Xiangya Hospital Central South University, Changsha

RECRUITING

Union Hospital Tongji Medical College, Huazhong University Of Science And Technology, Wuhan

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

The Fifth Affiliated Hospital Sun Yat sen University, Zhuhai